Skip to main content
Clinical Trials/ISRCTN48682427
ISRCTN48682427
Completed
Not Applicable

Directly Observed antiretroviral Therapy for people living with Human Immunodeficiency Virus (HIV) and Acquired ImmunDeficiency Syndrome (AIDS): a randomised controlled trial

Ministry of Health (Brazil)0 sites0 target enrollmentMarch 2, 2004

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Ministry of Health (Brazil)
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 2, 2004
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional

Investigators

Sponsor
Ministry of Health (Brazil)

Eligibility Criteria

Inclusion Criteria

  • 1\. HIV\-1 infected individuals
  • 2\. 18 years old or older
  • 3\. Starting antiretroviral therapy in three AIDS clinics in Porto Alegre (Brazil)

Exclusion Criteria

  • Not provided at time of registration

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Highly active anti-retroviral therapy including nevirapine once daily versus twice daily after at least 12 weeks of nevirapine twice daily. A randomized, open, multicentre trial.
ISRCTN81305260Institute of Biomedical Investigations of Bellvitge (Institut d'Investigació Biomèdica de Bellvitge) (IDIBELL) (Spain)308
Active, not recruiting
Phase 1
Initiation of first-line antiretroviral treatment with TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the first clinical contact in France: Trial IMEA 055 – FASTHIV positive age > 18 years -newly diagnosed HIV-infected individual evidenced by any tests -antiretroviral-treatment naive -negative urine pregnancy test -willing to sign an informed written consent– -regular health insurance -willing to provide two distinct contact information (telephone number and/or email) in order to be easily reached if needed between Day 0 and Day 7Therapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2019-000812-27-FRIMEA110
Completed
Not Applicable
Highly Active Antiretroviral Treatment (HAART) of Human Immunodeficiency Virus (HIV)-infection in a town in Cameroon: randomised controlled study to suggest which treatment starting point is most beneficial for the patientsHIV infectionInfections and InfestationsHIV
ISRCTN22114173Institute of Community Medicine, University of Tromsø (Norway)100
Not yet recruiting
Phase 1
Immunological and Virucidal effect of Amrita Tablet for Prevention of HIV AIDS
CTRI/2024/01/062079Satyananda yoga and Ayurveda Research institute Motihari
Active, not recruiting
Phase 1
Short pulse antiretroviral therapy at HIV seroconversion:A multi-centre randomised trial of therapeutic intervention at primary HIV-1 infection. Tratamiento antirretroviral en pulsos cortos en la seroconversión por el VIH: ensayo clínico aleatorizado, multicéntrico, de intervención terapéutica en la infección primaria por VIH-1. - SPARTACprimary HIV infection infección primaria por el VIHMedDRA version: 9.1 Level: LLT Classification code 10058427 Term: Primary HIV infection
EUCTR2004-000446-20-ESImperial College371